株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

寒冷凝集素症(CAD)- 市場洞察、疫学、市場予測 2028年

Cold Agglutinin Disease (CAD) - Market Insights, Epidemiology, and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 911509
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
寒冷凝集素症(CAD)- 市場洞察、疫学、市場予測 2028年 Cold Agglutinin Disease (CAD) - Market Insights, Epidemiology, and Market Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 150 Pages
概要

新興10カ国(トルコ、ロシア、サウジアラビア、アラブ首長国連邦、メキシコ、コロンビア、ブラジル、アルゼンチン、中国、台湾)の寒冷凝集素症(CAD)の2017年の有病数は2万9,077人、その市場規模は約2,680万米ドルと推計されています。

当レポートでは、新興10カ国(トルコ、ロシア、サウジアラビア、アラブ首長国連邦、メキシコ、コロンビア、ブラジル、アルゼンチン、中国、台湾)の寒冷凝集素症(CAD)市場を調査し、市場および疾病の概要、性別・タイプ・年齢・国別の疫学的予測、アンメットニーズ、新薬の概要、全体および各国の市場規模の推移と予測、市場の成長要因および障壁の分析などをまとめています。

目次

第1章 重要洞察

第2章 寒冷凝集素症(CAD)市場の概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 寒冷凝集素症(CAD):疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • クローン性と組織病理学
  • 病因
  • 診断

第4章 疫学および患者人口:地域別

  • 主な調査結果

第5章 新興10カ国の疫学

  • 新興10カ国の寒冷凝集素症(CAD)有病数

第6章 寒冷凝集素症(CAD)の疫学

  • 仮定と根拠
  • アジア
    • 台湾
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • 中国
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
  • 中東
    • サウジアラビア
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • アラブ首長国連邦
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
  • 東欧
    • ロシア
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • トルコ
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
  • ラテンアメリカ
    • メキシコ
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • ブラジル
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • アルゼンチン
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • コロンビア
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別

    第7章 寒冷凝集素症(CAD)の治療と管理

    • 治療アルゴリズム
    • 原発性自己免疫性溶血性貧血の診断と管理

    第8章 アンメットニーズ

    第9章 新薬

    • キークロスコンペティション
    • Sutimlimab(BIVV009):Bioverativ Therapeutics
      • 医薬品概要
      • その他の開発動向
      • 臨床開発
      • 安全性と有効性
      • 製品プロファイル
    • APL-2(Pegcetacoplan):Apellis Pharmaceuticals

    第10章 その他の有望な候補薬

    • Bortezomib:Janssen Pharmaceutical
      • 医薬品概要
      • その他の開発動向
      • 臨床開発
      • 安全性と有効性
      • 製品プロファイル
    • Parsaclisib:Incyte Corporation
    • KZR-616:Kezar Life Sciences

    第11章 寒冷凝集素症(CAD):新興10カ国の分析

    • 主な調査結果
    • 新興10カ国の寒冷凝集素症(CAD)の市場規模

    第12章 市場の見通し

    • 新興市場:市場の見通し
    • アジア(台湾・中国)
      • 台湾
        • 寒冷凝集素症(CAD)の総市場規模
        • 寒冷凝集素症(CAD)の市場規模:治療薬別
      • 中国
    • 中東
      • サウジアラビア
      • アラブ首長国連邦
    • 東欧
      • ロシア
      • トルコ
    • ラテンアメリカ
      • メキシコ
      • ブラジル
      • アルゼンチン
      • コロンビア

第13章 市場の成長要因

第14章 市場の障壁

第15章 キーオピニオンリーダーの意見

第16章 付録

  • 調査手法

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

図表

List of Tables

  • Table 1: Autoimmune Hemolytic Anemia Consisting of Warm, Cold, or Mixed Reactive Antibodies
  • Table 2: Diagnostic criteria for cold agglutinin disease
  • Table 3: Total Prevalence of Cold agglutinin disease in 10 Emerging Markets (2017-2028)
  • Table 4: Prevalent Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 5: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 6: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 7: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 8: Prevalent Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 9: Gender-specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 10: Type-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 11: Age-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 12: Prevalent Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 13: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 14: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 15: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 16: Prevalent Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 17: Gender-specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 18: Type-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 19: Age-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 20: Prevalent Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 21: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 22: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 23: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 24: Prevalent Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 25: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 26: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 27: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 28: Prevalent Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 29: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 30: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 31: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 32: Prevalent Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 33: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 34: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 35: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 36: Prevalent Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 37: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 38: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 39: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 40: Prevalent Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Table 41: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Table 42: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Table 43: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Table 44: Response definitions in cold agglutinin disease.
  • Table 45: Pharmacologic treatment options for relapsed or refractory CAD from case series
  • Table 46: Treatment of primary CHAD: Recommendations
  • Table 47: CHAD, Cold agglutinins, and surgery: Recommendations
  • Table 48: Emerging Drugs Analysis
  • Table 49: Sutimlimab, Clinical Trial Description, 2019
  • Table 50: APL-2, Clinical Trial Description, 2019
  • Table 51: Bortezomib, Clinical Trial Description, 2019
  • Table 52: Parsaclisib, Clinical Trial Description, 2019
  • Table 53: KZR-616, Clinical Trial Description, 2019
  • Table 54: Market size of Cold agglutinin disease in 10 Emerging Markets (2017-2028)
  • Table 55: Market Size of Cold Agglutinin Disease (CAD) in Taiwan, USD Million (2017-2028)
  • Table 56: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 57: Total Market Size of Cold Agglutinin Disease (CAD) in China, USD Million (2017-2028)
  • Table 58: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 59: Market Size of Cold Agglutinin Disease (CAD) in Saudi Arabia, USD Million (2017-2028)
  • Table 60: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 61: Market Size of CAD in UAE, USD Million (2017-2028)
  • Table 62: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 63: Market Size of CAD in Russia, USD Million (2017-2028)
  • Table 64: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 65: Market Size of CAD in Turkey, USD Million (2017-2028)
  • Table 66: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 67: Market Size of CAD in Mexico, USD Million (2017-2028)
  • Table 68: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 69: Market Size of Cold Agglutinin Disease (CAD) in Brazil, USD Million (2017-2028)
  • Table 70: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 71: Market Size of Cold Agglutinin Disease (CAD) in Argentina, USD Million (2017-2028)
  • Table 72: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Table 73: Market Size of Cold Agglutinin Disease (CAD) in Colombia, USD Million (2017-2028)
  • Table 74: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Common symptoms of cold agglutinin disease
  • Figure 2: The complement cascade
  • Figure 3: Complement-mediated hemolysis in cold agglutinin disease
  • Figure 4: Total Prevalence of Cold agglutinin disease in 10 Emerging Markets (2017-2028)
  • Figure 5: Prevalent Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 6: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 7: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 8: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 9: Prevalent Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 10: Gender-specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 11: Type-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 12: Age-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 13: Prevalent Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 14: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 15: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 16: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 17: Prevalent Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 18: Gender-specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 19: Type-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 20: Age-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 21: Prevalent Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 22: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 23: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 24: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 25: Prevalent Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 26: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 27: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 28: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 29: Prevalent Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 30: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 31: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 32: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 33: Prevalent Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 34: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 35: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 36: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 37: Prevalent Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 38: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 39: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 40: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 41: Prevalent Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 42: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 43: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 44: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 45: Therapeutic pathway for cold agglutinin disease
  • Figure 46: Unmet Needs
  • Figure 47: Total Market Size of Cold Agglutinin Disease (CAD) in 10 EM (2017-2028)
  • Figure 48: Market Size of Cold Agglutinin Disease (CAD) in Taiwan, USD Million (2017-2028)
  • Figure 49: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 50: Total Market Size of Cold Agglutinin Disease (CAD) in China, USD Million (2017-2028)
  • Figure 51: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 52: Market Size of CAD in Saudi Arabia, USD Million (2017-2028)
  • Figure 53: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 54: Market Size of CAD in UAE, USD Million (2017-2028)
  • Figure 55: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 56: Market Size of Cold Agglutinin Disease (CAD) in Russia, USD Million (2017-2028)
  • Figure 57: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 58: Market Size of CAD in Turkey, USD Million (2017-2028)
  • Figure 59: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 60: Market Size of CAD in Mexico, USD Million (2017-2028)
  • Figure 61: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 62: Market Size of Cold Agglutinin Disease (CAD) in Brazil, USD Million (2017-2028)
  • Figure 63: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 64: Market Size of Cold Agglutinin Disease (CAD) in Argentina, USD Million (2017-2028)
  • Figure 65: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 66: Market Size of Cold Agglutinin Disease (CAD) in Colombia, USD Million (2017-2028)
  • Figure 67: Market Size of Cold Agglutinin Disease (CAD) by Therapies in USD Million (2017-2028)
  • Figure 68: Market Drivers
  • Figure 69: Market Barriers
目次
Product Code: DIMI0675

DelveInsight's 'Cold Agglutinin Disease (CAD)- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China and Taiwan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted market size of CAD from 2017 to 2028 segmented by 10 emerging markets.

CAD is an uncommon autoimmune hemolytic anemia (AIHA) in which a well-defined, clonal low-grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. CAD is mediated by cold agglutinins (CA), without any obvious underlying disease, such as aggressive lymphoma, other overt malignancies, or specific infections. CA are able to agglutinate red blood cells (RBC) at an optimum temperature of 3-4°C, but are also active at higher temperatures, depending on the thermal amplitude.

Overall, the global Cold Agglutinin Disease therapeutics market has increased over the past few years. The market size is further expected to increase by the major drivers such as rising prevalence and awareness of the disease, current advancements in R&D, promising results of therapies and upcoming therapies in the forecast period [2017-2028].

Geography Covered

  • Asia (Taiwan and China)
  • Middle East (Saudi Arabia and UAE)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina, and Colombia)

Study Period: 2017-2028

CAD - Disease Understanding and Treatment Algorithm

CAD is a type of AIHA's which consist of warm, cold, or mixed-reactive antibody types that are directed against antigens on the red blood cell (RBC) surface. The autoantibodies may be idiopathic (primary) or related to an underlying condition, such as infection, malignancy, or immune disease (secondary).

Based on the autoantibodies, CAD is classified as primary (unknown cause) or secondary (caused by an underlying condition). Primary Cold Agglutinin Disease is used to describe patients without other systemic autoimmune disease or infective etiology and who have no clinical or radiological evidence of underlying lymphoma. Secondary Cold Agglutinin Disease, is mediated by hemolytic anemia occasionally complicating other specific diseases, such as B cell neoplasias (CLL, Waldenstrom macroglobulinemia, myeloma, other lymphomas), solid tumors (squamous carcinoma of the lung, metastatic adenocarcinoma of the colon, basal cell carcinoma, metastatic adrenal carcinoma, mixed parotid tumor), infections (most frequently Mycoplasma pneumonia, Epstein-Barr virus) or autoimmune diseases (scleroderma, primary Sjogren's syndrome, adult Still's disease, SLE, rheumatoid arthritis). The responsible antibody is monoclonal IgM in B-cell neoplasias and solid tumors and polyclonal IgM in infections, connective tissue diseases, and non-Hodgkin lymphomas.

Emerging markets also does not possess any approved therapy for CAD and relies only on the symptomatic treatment alternatives.

The current therapeutic market of CAD is dominated by non-pharmacological (cold avoidance) and pharmacological management. Corticosteroids, Alkylating agents, Purine nucleoside analogs and majorly Biologics, such as Rituximab monotherapy or combination therapy (Fludarabine and Rituximab, Bendamustine and Rituximab) and others are the major therapeutic line of treatment for CAD.

CAD Epidemiology

The CAD epidemiology division provides insights about historical and current patient pool and forecasted trends of 10EM countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent cases, Gender-Specific Prevalence, Age-Specific Prevalence and Type-Specific Prevalent cases of CAD ) scenario of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China and Taiwan. 2017-2028.

According to DelveInsight, the total prevalent cases of CAD in the 10EM was found to be 29,077 in 2017. The prevalence of CAD in the 10EM is expected to increase during the study period of 2017-2028.

CAD Drug Chapters

This segment of the CAD report encloses the detailed analysis of emerging drugs and other promising drugs. It also helps to understand the clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Pharmacological management of Cold Agglutinin disease included corticosteroids, alkylating agents, purine nucleoside analogs and biologics, such as Rituximab monotherapy or combination therapy (Fludarabine and Rituximab, Bendamustine and Rituximab), in some cases, Bortezomib alone or in combination can also be used. These are used as the mainstay of treatment in emerging markets.

Rituximab monotherapy is recommended as the first-line treatment and several case reports indicate that Rituximab is an effective drug in some cases of CAD. Since Rituximab has been in use, the reduction in the numbers of cold antibodies has caused a significant improvement in hemoglobin levels. Patients who relapse after having responded to Rituximab may receive another course of Rituximab or proceed to the combination therapy, depending on an individualized assessment.

Detailed chapters of emerging therapies such as Sutimlimab (BIVV009) (Sanofi), APL-2 (Pegcetacoplan) (Apellis Pharmaceuticals) and promising Bortezomib (Janssen Pharmaceutical), Parsaclisib (Incyte Corporation), and others have also been provided in the report.

CAD Market Outlook

The CAD market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

According to DelveInsight, the market for CAD in 10EM was found to be approximately USD 26.80 Million in 2017.

China accounted for 33% of the total market of CAD in 2017. Due to the high prevalence of this disease in the region, the CAD treatment market in China is expected to dominate the market during the forecast period (2019-2028).

CAD Drugs Uptake

This section focusses on the emerging drugs present in the market and promising drugs in the market or the drugs that are expected to get launched in the market during the study period from 2017-2028. The analysis covers patient uptake by therapies and sales of each drug.

The launch of Complement pathway inhibitors such as Sutimlimab (Sanofi), APL-2 (Apellis Pharmaceuticals) is anticipated to revolutionize the overall market scenario.

CAD Report Insights

  • Patient Population of CAD
  • Therapeutic Approaches
  • Pipeline Analysis
  • Emerging Trends
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

CAD Report Key Strengths

  • 10-Year Forecast
  • 10 EM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

CAD Report Assessment

  • Pipeline Product Profiles
  • Key Product and Key Players
  • Unmet Needs
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving CAD market
  • Organize sales and marketing efforts by identifying the best opportunities for the CAD market
  • To understand the future market competition in the CAD market

Table of Contents

1. Key Insights

2. Cold Agglutinin Disease Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Cold Agglutinin Disease in 2017
  • 2.2. Market Share (%) Distribution of Cold Agglutinin Disease in 2028

3. Cold Agglutinin Disease: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Clonality and Histopathology
  • 3.4. Pathogenesis
  • 3.5. Diagnosis

4. Epidemiology and Patient Population - By Region

  • 4.1. Key Findings

5. Ten Emerging Markets (10EM) - Epidemiology

  • 5.1. Total Prevalence of Cold agglutinin disease in 10 Emerging Markets

6. Region Wise-Epidemiology of Cold Agglutinin Disease (CAD)

  • 6.1. Assumptions and Rationale
  • 6.2. Asia [Taiwan and China]
  • 6.3. Taiwan
    • 6.3.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Taiwan
    • 6.3.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
    • 6.3.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
    • 6.3.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
  • 6.4. China
    • 6.4.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.5. Middle East [Saudi Arabia and UAE]
  • 6.5. Saudi Arabia
    • 6.5.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
    • 6.5.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
    • 6.5.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
    • 6.5.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
  • 6.6. UAE
    • 6.6.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in the UAE
    • 6.6.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
    • 6.6.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
    • 6.6.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
  • 6.7. Eastern Europe [Russia and Turkey]
  • 6.8. Russia
    • 6.8.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Russia
    • 6.8.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
    • 6.8.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
    • 6.8.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
  • 6.9. Turkey
    • 6.9.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Turkey
    • 6.9.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
    • 6.9.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
    • 6.9.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
  • 6.10. LATAM [Mexico, Brazil, Argentina and Colombia]
  • 6.11. Mexico
    • 6.11.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Mexico
    • 6.11.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
    • 6.11.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
    • 6.11.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
  • 6.12. Brazil
    • 6.12.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Brazil
    • 6.12.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
    • 6.12.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
    • 6.12.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
  • 6.13. Argentina
    • 6.13.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Argentina
    • 6.13.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
    • 6.13.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
    • 6.13.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
  • 6.14. Colombia
    • 6.14.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Colombia
    • 6.14.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia
    • 6.14.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia
    • 6.14.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia

7. Treatment and Management of Cold agglutinin disease

  • 7.1. Treatment algorithm
  • 7.2. The diagnosis and management of primary autoimmune hemolytic anemia-UK based experts

8. Unmet Needs

9. Emerging Drugs

  • 9.1. Key Cross Competition
  • 9.2. Sutimlimab (BIVV009): Bioverativ Therapeutics (Sanofi)
    • 9.2.1. Drug Description
    • 9.2.2. Other Developmental Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile
  • 9.3. APL-2 (Pegcetacoplan): Apellis Pharmaceuticals
    • 9.3.1. Drug Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Product Profile

10. Other Promising Candidates

  • 10.1. Bortezomib: Janssen Pharmaceutical
    • 10.1.1. Drug Description
    • 10.1.2. Other Developmental Activities
    • 10.1.3. Clinical Development
    • 10.1.4. Safety and Efficacy
    • 10.1.5. Product Profile
  • 10.2. Parsaclisib: Incyte Corporation
    • 10.2.1. Drug Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Product Profile
  • 10.3. KZR-616: Kezar Life Sciences
    • 10.3.1. Drug Description
    • 10.3.2. Other Developmental Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile

11. Cold Agglutinin Disease (CAD): 10 EM Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of Cold Agglutinin Disease (CAD) in 10 EM

12. Market Outlook

  • 12.1. Emerging Markets: Market Outlook
  • 12.2. Asia [Taiwan and China]
  • 12.3. Taiwan
    • 12.3.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.3.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.4. China
    • 12.4.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.4.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.5. Middle East [Saudi Arabia and UAE]
  • 12.6. Saudi Arabia
    • 12.6.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.6.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.7. UAE
    • 12.7.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.7.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.8. Eastern Europe [Russia and Turkey]
  • 12.9. Russia
    • 12.9.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.9.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.10. Turkey
    • 12.10.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.10.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.11. LATAM [Mexico, Brazil, Argentina and Colombia]
  • 12.12. Mexico
    • 12.12.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.12.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.13. Brazil
    • 12.13.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.13.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.14. Argentina
    • 12.14.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.14.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies
  • 12.15. Colombia
    • 12.15.1. Total Market Size of Cold Agglutinin Disease (CAD)
    • 12.15.2. Market Size of Cold Agglutinin Disease (CAD) by Therapies

13. Market Drivers

14. Market Barriers

15. KOL Views

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Back to Top